|
 |
حجز الاسم التجاري |
|
|
تحذير
الأسماء التجاريه المختلفه قد تحتوي علي محتوي إضافات مختلفة حسب الدوله و المعمل
|
|
Idacrybin |
المكسيك |
|
Idamen |
تركيا |
|
Idamycin |
المكسيك, الولايات المتحدة, كندا |
|
Idaralem |
كولومبيا |
|
Ondarubin |
المكسيك |
|
Rubixina |
بيرو |
|
Zavedos |
أستراليا, ألمانيا, أيسلندا, إسبانيا, إيران, إيطاليا, الإكوادور, البرازيل, البرتغال, الدنمارك, السويد, المغرب, النرويج, النمسا, ايرلندا, بريطانيا العظمي, بلجيكا, بولندا, تركيا, تشيلي, تونس, رومانيا, زيلاندا الجديدة, سلوفينيا, فرنسا, فنزويلا, فنلندا, كرواتيا, كولومبيا, لوكسمبورغ, ماليزيا, هنغاريا, هولندا, يونان |
|
|
 |
 |
مراجع : Idarubicin hydrochloride |
|
|
نوع |
منشور |
| 3 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
مجلة |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
مجلة |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
مجلة |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 249 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 307 |
مجلة |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 335 |
مجلة |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 491 |
مجلة |
Turowski RC, Durthaler JM.
Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2181-2184. |
| 632 |
مجلة |
Beijnen JH, Rosing H, De Vries PA, Underberg WJM.
Stability of anthracycline antitumour agents in infusion fluids.
J Parenter Sci Technol 1985 ; 39: 220-222. |
| 905 |
مجلة |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
مجلة |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
مجلة |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1496 |
مجلة |
Trissel LA, Martinez JF, Gilbert DL.
Screening cladribine for Y-site physical compatibility with selected drugs.
Hosp Pharm 1996 ; 31: 1425-1428. |
| 3474 |
مختبر |
Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009 |
| 3526 |
مختبر |
Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010 |
| 3595 |
مختبر |
Aciclovir - Summary of Product Characteristics
Hospira 2009 |
| 3637 |
مختبر |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014 |
| 4661 |
مجلة |
Bourcier B, Lagarce R, Lebreton V.
Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization
J Pharm Biomed Anal 2022 |
| 5075 |
مختبر |
IDARUBICINE ACCORD 5 mg/5 ml, solution pour perfusion - Résumé des caractéristiques du produit.
ACCORD HEALTHCARE FRANCE SAS 2024 |
|
|
